DCM
BVS icon

Dean Capital Management’s Bioventus BVS Stock Holding History

Dean Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,595
Closed -$601K – 78
2022
Q1 		$601K Sell
42,595
-5,484
-11% -$73.4K 0.52% 57
2021
Q4 		$697K Buy
48,079
+6,402
+15% +$91K 0.6% 59
2021
Q3 		$590K Buy
+41,677
New +$641K 0.55% 64

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Dean Capital Management's BVS Position: Q2 2022 in Review

Dean Capital Management sold out of Bioventus (BVS) in Q2 2022, closing a stake of 42,595 shares — an estimated $601K sold.

Dean Capital Management first reported a position in BVS in Q3 2021 and held it in 3 quarters. The position peaked at $697K in Q4 2021. 98 funds tracked by Wall St. Rank hold BVS as of Q2 2022.

  • Dean Capital Management reported no remaining Bioventus position as of Q2 2022 after selling out during the quarter.
  • Dean Capital Management sold 42,595 Bioventus shares in Q2 2022, an estimated $601K.
  • Dean Capital Management first reported a position in Bioventus in Q3 2021 and held it in 3 quarters.
  • Dean Capital Management's Bioventus position peaked at $697K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held Bioventus as of Q2 2022.

Based on Dean Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.